DOI 10.1016/j.xcrm.2026.103113
Isobavachalcone targets deubiquitinase OTUB1 to induce PD-L1 degradation and enhances antitumor immunity.
Аннотация
PD-L1-mediated immunosuppression is a key mechanism underlying tumor immune evasion, whereas PD-1/PD-L1 blockade therapies remain limited by low response rates and acquired resistance. Through small-molecule screening, we identify isobavachalcone (IBC), a naturally derived compound that modulates PD-L1 homeostasis by targeting the deubiquitinase OTUB1. Mechanistically, IBC targets OTUB1 at the His217 residue and suppresses its deubiquitinase activity, thereby promoting K48-linked polyubiquitination of PD-L1 and its proteasome-dependent degradation. Functionally, IBC reduces tumor cell PD-L1 expression and enhances CD8+ T cell-mediated cytotoxicity. In PD-L1-deficient tumor models, IBC fails to further enhance antitumor activity, indicating that PD-L1 is required for IBC-mediated immune regulation. Moreover, IBC combined with anti-CTLA-4 therapy further enhanced antitumor efficacy. Together, these findings highlight IBC as a potential drug candidate that promotes PD-L1 degradation and demonstrate the therapeutic potential of targeting the OTUB1-PD-L1 axis to improve immune checkpoint therapy.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.